A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma

Journal of Lipid Research

Volumn 49, Issue 10, 2008, Pages 2230-2239

  Bergmark, Claes ^a   Dewan, Asheesh ^b   Orsoni, Alexina ^c   Merki, Esther ^b   Miller, Elizabeth R ^b   Shin, Min Jeong ^d   Binder, Christoph J ^b,e   Hörkkö, Sohvi ^b   Krauss, Ronald M ^f   Chapman, M John ^c   Witztum, Joseph L ^b   Tsimikas, Sotirios ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSERM   (France)

^d Yonsei University College of Medicine   (South Korea)

^e CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atherosclerosis; Cholesterol; Lipids; Lipoproteins; Oxidation

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B100; LIPOPROTEIN A; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; PHOSPHORYLCHOLINE;

ADULT; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; IN VITRO STUDY; MALE; PHOSPHOLIPID TRANSFER; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOPRECIPITATION; LIPOPROTEIN(A); MALE; MIDDLE AGED; OXIDATION-REDUCTION; PHOSPHOLIPIDS; SUBSTRATE SPECIFICITY; ULTRACENTRIFUGATION;

EID: 59049086968     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800174-JLR200     Document Type: Article

References (44)

1. Berg, K. 1963. A new serum type system in man - the LP system. Acta Pathol. Microbiol. Scand. 59: 369-382.
2. Hobbs, H. H., and A. L. White. 1999. Lipoprotein(a): intrigues and insights. Curr. Opin. Lipidol. 10: 225-236.
3. Scanu, A. M., K. Nakajima, and C. Edelstein. 2001. Apolipoprotein (a): structure and biology. Front. Biosci. 6: D546-D554.
4. Utermann, G. 1989. The mysteries of lipoprotein(a). Science. 246: 904-910.
5. Kostner, K. M., and G. M. Kostner. 2002. Lipoprotein(a): still an enigma? Curr. Opin. Lipidol. 13: 391-396.
6. Berglund, L., and R. Ramakrishnan. 2004. Lipoprotein(a): An elusive cardiovascular risk factor. Arterioscler. Thromb. Vasc. Biol. 24: 2219-2226.
7. Danesh, J., R. Collins, and R. Peto. 2000. Lipoprotein(a) and coronary artery disease. Metaanalysis of prospective studies. Circulation. 102: 1082-1085.
8. Tsimikas, S., E. S. Brilakis, E. R. Miller, J. P. McConnell, R. J. Lennon, K. S. Kornman, J. L. Witztum, and P. B. Berger. 2005. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353: 46-57.
9. Suk, D. J., N. Rifai, J. E. Buring, and P. M. Ridker. 2006. Lipoprotein (a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. J. Am. Med. Assoc. 296: 1363-1370.
10. Lawn, R. M., N. W. Boonmark, K. Schwartz, G. E. Lindahl, D. P. Wade, C. D. Byrne, K. J. Fong, K. Meer, and L. Patthy. 1995. The recurring evolution of lipoprotein(a). J. Biol. Chem. 270: 24004-24009.
11. Caplice, N. M., C. Panetta, T. E. Peterson, L. S. Kleppe, C. S. Mueske, G. M. Kostner, G. J. Broze, Jr., and R. D. Simari. 2001. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood. 98: 2980-2987.
12. Tsimikas, S., C. Bergmark, R. W. Beyer, R. Patel, J. Pattison, E. Miller, J. Juliano, and J. L. Witztum. 2003. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J. Am. Coll. Cardiol. 41: 360-370.
13. Edelstein, C., D. Pfaffinger, J. Hinman, E. Miller, G. Lipkind, S. Tsimikas, C. Bergmark, G. S. Getz, J. L. Witztum, and A. M. Scanu. 2003. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J. Biol. Chem. 278: 52841-52847.
14. Silaste, M. L., M. Rantala, G. Alfthan, A. Aro, J. L. Witztum, Y. A. Kesaniemi, and S. Horkko. 2004. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein (a). Arterioscler. Thromb. Vasc. Biol. 24: 498-503.
15. Tsimikas, S., H. K. Lau, K. R. Han, B. Shortal, E. R. Miller, A. Segev, L. K. Curtiss, J. L. Witztum, and B. H. Strauss. 2004. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 109: 3164-3170.
16. Tsimikas, S., J. L. Witztum, E. R. Miller, W. J. Sasiela, M. Szarek, A. G. Olsson, and G. G. Schwartz. 2004. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 110: 1406-1412.
17. Rodenburg, J., M. N. Vissers, A. Wiegman, E. R. Miller, P. M. Ridker, J. L. Witztum, J. J. Kastelein, and S. Tsimikas. 2006. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J. Am. Coll. Cardiol. 47: 1803-1810.
18. Tsimikas, S., S. Kiechl, J. Willeit, M. Mayr, E. R. Miller, F. Kronenberg, Q. Xu, C. Bergmark, S. Weger, F. Oberhollenzer, et al. 2006. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results fromthe Bruneck study. J. Am. Coll. Cardiol. 47: 2219-2228.
19. Kiechl, S., J. Willeit, M. Mayr, B. Viehweider, M. Oberhollenzer, F. Kronenberg, C. J. Wiedermann, S. Oberthaler, Q. Xu, J. L. Witztum, et al. 2007. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes. Prospective results from the Bruneck Study. Arterioscler. Thromb. Vasc. Biol. 27: 1788-1795.
20. Berg, K., G. Dahlen, B. Christophersen, T. Cook, J. Kjekshus, and T. Pedersen. 1997. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin. Genet. 52: 254-261.
21. Berg, K., and O. C. Ro. 1991. Lp(a) lipoprotein level and longevity. Ann. Genet. 34: 264-269.
22. Pillarisetti, S., L. Paka, J. C. Obunike, L. Berglund, and I. J. Goldberg. 1997. Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J. Clin. Invest. 100: 867-874.
23. Tsironis, L. D., C. S. Katsouras, E. S. Lourida, J. V. Mitsios, J. Goudevenos, M. Elisaf, and A. D. Tselepis. 2004. Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis. 177: 193-201.
24. Hõrkkõ, S., D. A. Bird, E. Miller, H. Itabe, N. Leitinger, G. Subbanagounder, J. A. Berliner, P. Friedman, E. A. Dennis, L. K. Curtiss, et al. 1999. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103: 117-128.
25. Friedman, P., S. Hörkkö, D. Steinberg, J. L. Witztum, and E. A. Dennis. 2001. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids: importance of Schiff base formation and Aldol condensation. J. Biol. Chem. 277: 7010-7020.
26. Witztum, J. L., S. G. Young, R. L. Elam, T. E. Carew, and M. Fisher. 1985. Cholestyramine-induced changes in low density lipoprotein composition and metabolism. I. Studies in the guinea pig. J. Lipid Res. 26: 92-103.
27. Chapman,M. J., S. Goldstein, D.Lagrange, and P. M. Laplaud. 1981. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res. 22: 339-358.
28. Boullier, A., P. Friedman, R. Harkewicz, K. Hartvigsen, S. R. Green, F. Almazan, E. A. Dennis, D. Steinberg, J. L. Witztum, and O. Quehenberger. 2005. Phosphocholine as a pattern recognition ligand for CD36. J. Lipid Res. 46: 969-976.
29. Gillotte-Taylor, K., A. Boullier, J. L. Witztum, D. Steinberg, and O. Quehenberger. 2001. Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. J. Lipid Res. 42: 1474-1482.
30. Gillotte, K. L., S. Horkko, J. L. Witztum, and D. Steinberg. 2000. Oxidized phospholipids, linked to apolipoprotein B of oxidized LDL, are ligands for macrophage scavenger receptors. J. Lipid Res. 41: 824-833.
31. Devlin, C. M., S. J. Lee, G. Kuriakose, C. Spencer, L. Becker, I. Grosskopf, C. Ko, L. S. Huang, M. L. Koschinsky, A. D. Cooper, et al. 2005. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Arterioscler. Thromb. Vasc. Biol. 25: 1704-1710.
32. Tsimikas, S., M. Aikawa, F. J. Miller, Jr., E. R. Miller, M. Torzewski, S. R. Lentz, C. Bergmark, D. D. Heistad, P. Libby, and J. L. Witztum. 2007. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscler. Thromb. Vasc. Biol. 27: 175-181.
33. Reardon, C. A., E. R. Miller, L. Blachowicz, J. Lukens, C. J. Binder, J. L. Witztum, and G. S. Getz. 2004. Autoantibodies to OxLDL fail to alter the clearance of injected OxLDL in apolipoprotein E-deficient mice. J. Lipid Res. 45: 1347-1354.
34. Schneider, M., J. L. Witztum, S. G. Young, E. H. Ludwig, E. R. Miller, S. Tsimikas, L. K. Curtiss, S. M. Marcovina, J. M. Taylor, R. M. Lawn, et al. 2005. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J. Lipid Res. 46: 769-778.
35. Chang, M. K., C. J. Binder, Y. I. Miller, G. Subbanagounder, G. J. Silverman, J. A. Berliner, and J. L. Witztum. 2004. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J. Exp. Med. 200: 1359-1370.
36. Gargalovic, P. S., M. Imura, B. Zhang, N. M. Gharavi, M. J. Clark, J. Pagnon, W. P. Yang, A. He, A. Truong, S. Patel, et al. 2006. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc. Natl. Acad. Sci. USA. 103: 12741-12746.
37. Watson, A. D., N. Leitinger, M. Navab, K. F. Faull, S. Hörkkö, J. L. Witztum, W. Palinski, D. Schwenke, R. Salomon, W. Sha, et al. 1997. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/ endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272: 13597-13607.
38. Podrez, E. A., E. Poliakov, Z. Shen, R. Zhang, Y. Deng, M. Sun, P. J. Finton, L. Shan, M. Febbraio, D. P. Hajjar, et al. 2002. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277: 38517-38523.
39. Binder, C. J., P. X. Shaw, M. K. Chang, A. Boullier, K. Hartvigsen, S. Horkko, Y. I. Miller, D. A. Woelkers, M. Corr, and J. L. Witztum. 2005. The role of natural antibodies in atherogenesis. J. Lipid Res. 46: 1353-1363.
40. Binder, C. J., K. Hartvigsen, and J. L. Witztum. 2007. Promise of immune modulation to inhibit atherogenesis. J. Am. Coll. Cardiol. 50: 547-550.
41. Chang, M. K., C. Bergmark, A. Laurila, S. Hörkkö, K. H. Han, P. Friedman, E. A. Dennis, and J. L. Witztum. 1999. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc. Natl. Acad. Sci. USA. 96: 6353-6358.
42. Huber, J., A. Vales, G. Mitulovic, M. Blumer, R. Schmid, J. L. Witztum, B. R. Binder, and N. Leitinger. 2002. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler. Thromb. Vasc. Biol. 22: 101-107.
43. Blencowe, C., A. Hermetter, G. M. Kostner, and H. P. Deigner. 1995. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J. Biol. Chem. 270: 31151-31157.
44. Karabina, S. A., M. C. Elisaf, J. Goudevenos, K. C. Siamopoulos, D. Sideris, and A. D. Tselepis. 1996. PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro. Atherosclerosis. 125: 121-134.